Voluntis wins regulatory nod to integrate Toujeo insulin with Insulia mobile app
Voluntis said today its digital management system for people with Type II diabetes, Insulia, won FDA clearance and CE Mark approval to integrate Sanofi‘s (NYSE:SNY) Toujeo insulin glargine. The company’s software already works with Lantus and Levemir. The Insulia digital companion is composed of a patient mobile app and healthcare worker web portal. The app gives real-time basal insulin dosing recommendations and educational coaching messages based on blood glucose levels to patients with Type II diabetes. The web portal enables healthcare practitioners to develop personalized treatment plans and trac...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Health Information Technology Pharmaceuticals Regulatory/Compliance Software / IT Wall Street Beat Sanofi-Aventis Voluntis Source Type: news

Novo Nordisk eyes drug development program
Novo Nordisk (NYSE:NVO) is betting on a risky drug development strategy, like re-engineering insulin to act selectively on the liver or only when blood sugar is high, according to the Wall Street Journal. Nordisk has focused on developing fast-acting insulin to inject at mealtime and another variety for a steady supply of insulin throughout the day. Its most recent insulin product, Tresiba, provides a near-stable level of insulin in the blood for 40 hours. Tresiba sells for $443.85 for 15 milliliters, 10% higher than its predecessor Levemir. “The next steps will take innovation to an even higher level,&rdqu...
Source: Mass Device - October 3, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Business/Financial News Diabetes Research & Development Novo Nordisk Source Type: news

Insulin Nasal Spray as Treatment for Alzheimer's Dementia
The study's subjects were 60 adults diagnosed with amnesic mild cognitive impairment (MCI) or mild to moderate Alzheimer's dementia (AD). Those who received nasally-administered 40 international unit (IU) doses of insulin detemir, a manufactured form of the hormone, for 21 days showed significant improvement in their short-term ability to retain and process verbal and visual information compared with those who received 20 IU does or a placebo. (Source: Disabled World)
Source: Disabled World - January 11, 2015 Category: Disability Tags: Aging Associated Diseases Source Type: news

Nasal spray with insulin equivalent shows promise as treatment for adults with mild cognitive impairment, Alzheimer’s dementia
A human-made form of insulin delivered by nasal spray may improve working memory and other mental capabilities in adults with mild cognitive impairment and Alzheimer's disease dementia, according to a pilot study. The researchers also sought to determine if the insulin detemir doses would cause any negative side effects, and found only minor adverse reactions among the subjects. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 8, 2015 Category: Science Source Type: news

Insulin Analogues Have Edge in Curbing Severe HypoglycemiaInsulin Analogues Have Edge in Curbing Severe Hypoglycemia
Compared with human insulin, insulin detemir and aspart significantly reduce recurrent hypoglycemia in many type 1 diabetics prone to such events, according to Danish researchers. Nevertheless, individual responses vary. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 28, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Novo Nordisk’s NovoRapid and Levemir found to significantly reduce severe hypoglycaemia
Novo Nordisk's short-acting and long-acting modern insulin analogues NovoRapid (insulin aspart) and Levemir (insulin detemir) have significantly reduced severe hypoglycaemia in people with type 1 diabetes compared to human insulin (regular/NPH), acco… (Source: Drug Development Technology)
Source: Drug Development Technology - May 6, 2014 Category: Pharmaceuticals Source Type: news

Insulin in Patients With Diabetes and Declining KidneysInsulin in Patients With Diabetes and Declining Kidneys
How does insulin glargine and insulin detemir dosing change with changing renal function? Therapeutic Advances in Endocrinology and Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Novo Nordisk increased operating profit by 32% in 2012 (31 January 2013)
Sales growth of 18% driven by Victoza®, NovoRapid® and Levemir® Sales increased by 18% to 78.0 billion in Danish kroner and by 12% in local currencies. •Sales of modern insulins increased by 21% (15% in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2013 Category: Pharmaceuticals Source Type: news

Insulin Analogues Dosing and Costs -- Detemir vs GlargineInsulin Analogues Dosing and Costs -- Detemir vs Glargine
Which analog is more cost-effective? Insulin detemir or insulin glargine? BMC Endocrine Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 28, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Exenatide more effective than insulin detemir: study
NEW YORK (Reuters Health) - Exenatide is more effective than insulin detemir when added to oral glucose-lowering therapies, European researchers say. (Source: Modern Medicine)
Source: Modern Medicine - January 9, 2013 Category: Journals (General) Source Type: news

Once-weekly exenatide versus once- or twice-daily insulin detemir in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
This study is the first to compare EQW and insulin detemir, with respect to glycaemic control, body weight, lipids, safety, tolerability, and patient-reported outcomes in patients with type 2 diabetes whose diabetes was inadequately controlled with metformin (with or without sulfonylureas). Patients were randomised to EQW (2 mg) or detemir (once or twice daily, titrated to achieve fasting plasma ... (Source: NeLM - News)
Source: NeLM - News - January 4, 2013 Category: Drugs & Pharmacology Source Type: news